Loading company…
PharmNovo develops medicines for chronic pain, including the neuropathic pain candidate PN6047.
PharmNovo is developing PN6047, a delta-opioid receptor agonist intended to treat neuropathic pain without the addiction risks associated with conventional opioids. Founded in 2008 by Bengt von Mentzer and based in Lund, Sweden, the company is preparing a Phase 2 trial. In July 2026, it raised SEK 39 million from KDventures to advance the trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in